Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Antibe Therapeutics Inc(Pre-Merger)
ATBPF
Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,...
otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:ATBPF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
...
Next
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Jul 18, 2022 4:19pm
No luck ...
Not sure how many traded at 59 - but - could not get it below 62
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Jul 18, 2022 4:03pm
ATE @ 59 pennies
any questions INVESTOR RELATIONS Christina Cameron VP Investor Relations +1 416-577-1443 christina@antibethera.com good luck with geting answers.
(81)
•••
Stutters
X
View Profile
View Bullboard History
Post by
Stutters
on Jul 18, 2022 1:30pm
I said it would hit .40s
the price was above .70 cents. Always put you money on the opposite of what wafts out of Mugsys mouth
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Comment by
Duster340
on Jul 18, 2022 12:59pm
RE:Great work Mugsy
what was that bet what comes first $1.00 or 50 cents, looks like the 50 cent bet is looking good.
(81)
•••
Stutters
X
View Profile
View Bullboard History
Post by
Stutters
on Jul 18, 2022 11:11am
Great work Mugsy
mugsy posted on here he is scooping up all shares below .70 cents. Well.....i dont believe you.......again
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Jul 18, 2022 10:58am
Did john scare all the potential fish away?
(20)
•••
Hideaway
X
View Profile
View Bullboard History
Comment by
Hideaway
on Jul 16, 2022 12:00pm
RE:Strong buy rating
Duster,if you look at these analysts win-loss ratio and their average gain- loss rating,they have not done very well with their picks.In each instance,they have had a very low success rate with losses
...more
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Jul 15, 2022 11:30pm
Strong buy rating
Average price $4.15 https://www.tipranks.com/stocks/tse:ate/forecast
(33)
•••
Inthepez
X
View Profile
View Bullboard History
Comment by
Inthepez
on Jul 15, 2022 7:34pm
RE:Nice Try davgro/czechcashing
Below is the ramblings of a schizophrenic who caught in his own lies today. It's entertaining but sad lol
(55)
•••
StockingUp21
X
View Profile
View Bullboard History
Comment by
StockingUp21
on Jul 15, 2022 7:31pm
RE:Canaccord Drops Price Target To $0.70 Following Asset Sale
From $15 to $5 to $1.50 to $0.70
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Jul 15, 2022 6:44pm
RE:I would like to do lunch with...
haha you would fit in perfectly with those guys, glad you brought up oldfart's name another one of your buddies that thought he was smarter than everyone else i remeber him saying about 4 months
...more
(450)
•••
davgro
X
View Profile
View Bullboard History
Post by
davgro
on Jul 15, 2022 5:29pm
I would like to do lunch with...
Inthepez, Forestview, NewYorker, CzechCashing, Oldfart, quinlash and several other Stockhouse members but it appears that according to the Dumpster I would be eating alone due to my Dissociative
...more
(2)
•••
Doccole
X
View Profile
View Bullboard History
Comment by
Doccole
on Jul 15, 2022 5:13pm
RE:RE:Canaccord Drops Price Target To $0.70 Following Asset Sale
The delay that hasn't been announced to retail is why John was selling. These guys are full of the spin. Sorry retail. That's the other shoe we were waiting to drop!
(2)
•••
Doccole
X
View Profile
View Bullboard History
Comment by
Doccole
on Jul 15, 2022 5:10pm
RE:Canaccord Drops Price Target To $0.70 Following Asset Sale
Yep, what a joke. It's delayed because they have no idea about the science. this is more of a phase 1, pre clinical company.
(450)
•••
davgro
X
View Profile
View Bullboard History
Post by
davgro
on Jul 15, 2022 4:55pm
Canaccord Drops Price Target To $0.70 Following Asset Sale
It is important for ATE investors to hear all analyst opinions on the stock even if they are less than favourable. Here are some of the points in Canaccord Genuity's recent note on ATE's
...more
Prev
...
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >